Joerg Ahlgrimm, CEO of SK pharmteco, believes the CDMO industry is heading for significant consolidation: “If you fast forward 10 years, there will probably be 10-15 large, multi-modality CDMOs, with many smaller and specialised ones being bought.” Joerg Ahlgrimm brings
SK pharmteco, a global contract development, manufacturing, and analytical testing organization, has signed a memorandum of understanding (MOU) with South Korea-based biopharmaceutical company Rznomics Inc. The agreement establishes a multi-year strategic partnership focused on developing and commercializing RNA-based gene therapies.
“The best CDMO is the one you haven’t worked with.” says Audrey Greenberg.”That’s really unfortunate.. it’s not that hard to be a good service provider.” Audrey is the Founder of Centre for Breakthrough Medicines, the innovative, Pennsylvania-based Cell & Gene
SK bioscience has acquired a controlling stake in IDT Biologika, a German contract development and manufacturing organization (CDMO), for 339 billion won ($243.9 million). The deal, finalized through an agreement with the Klocke Group, gives SK bioscience 60% of IDT
SK Inc., the holding and investment company of South Korea’s SK Group, is in the final stages of negotiations to sell a major asset of its contract drug-making unit, SK Pharmteco Co., to Novo Nordisk A/S. The asset in question
